Novocure: Final patient enrolled TTFields combo study to treat pancreatic cancer

Novocure announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields, TTFields, together with nab-paclitaxel and gemcitabine for treatment of patients with locally advanced pancreatic cancer. "There is a severe unmet need for patients with pancreatic cancer," said Asaf Danziger, Novocure’s Chief Executive Officer. "Each year in the U.S. alone, approximately 43,000 people are diagnosed with unresectable pancreatic cancer; however, the five-year survival rate remains stagnant at just 10%. The completion of the PANOVA-3 study marks a critical milestone for our company and potentially for patients suffering from this deadly disease. We are proud to be adding to the evolving clinical research and are excited at the prospect of improving patient survival." Following the completion of enrollment, an independent Data Monitoring Committee will conduct a pre-specified interim analysis pursuant to the trial protocol. Patients will be followed for a minimum of 18 months.